|
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The transcription of several gene products was found to be either commonly overexpressed (i.e., RKIP, Bcl-2, and DR5) or underexpressed (i.e., Bcl-6 and TNFR2) in both pre-MM and MM.
|
28476134 |
2017 |
|
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
High BCL2 levels have been detected in most human lymphoid malignancies, not limited to follicular lymphoma (where the role of BCL2 overexpression is driven by the t[14;18] translocation) but also B-cell chronic lymphocytic leukemia (CLL) and multiple myeloma.
|
24095849 |
2014 |
|
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Multiple myeloma xenograft models that coexpressed BCL-XL or MCL-1 with BCL-2 were also resistant to venetoclax.
|
26939706 |
2016 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Small interfering RNA of cyclooxygenase-2 induces growth inhibition and apoptosis independently of Bcl-2 in human myeloma RPMI8226 cells.
|
17588340 |
2007 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, our data suggest that the protective effects of bcl-2 in MM cells act upstream in the NF-kappaB activation-signaling pathway and the potential use of NF-kappaB as a biomarker in progressive MM.
|
10216101 |
1999 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, our data demonstrates that loss of p53 function leads to myeloma cell progression and resistant phenotype through bcl-2-related mechanisms.
|
12479855 |
2003 |
|
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
JS-K induced apoptosis in MM cells, which was associated with PARP, caspase-8, and caspase-9 cleavage; increased Fas/CD95 expression; Mcl-1 cleavage; and Bcl-2 phosphorylation, as well as cytochrome c, apoptosis-inducing factor (AIF), and endonuclease G (EndoG) release.
|
17384201 |
2007 |
|
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Indeed, a reduction in the transcript levels for MET, a survival gene for MM, was detected as early as 4 h and transcripts were reduced to c. 10% of control after 48 h. Interestingly, no significant change in protein levels was observed for Bcl-2, XIAP, Mcl-1 or survivin.
|
18205859 |
2008 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that if BCL2 deregulation does indeed occur in MM, a mechanism other than translocation must be involved in most cases.
|
1415486 |
1992 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Myeloid cell leukemia-1 (Mcl-1, HGNC: 6943), a pro-survival member of the Bcl-2 family, plays a crucial role in Multiple Myeloma (MM) pathogenesis and drug resistance, thus representing a promising therapeutic target in MM.
|
24120758 |
2014 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Altogether, the identification of a subset of cell lines and primary cells effectively killed by ABT-737 alone supported the evaluation of ABT-263, an orally active counterpart to ABT-737, for the treatment of t(11;14) and hyperdiploid groups of myeloma harboring a Bcl-2(high)/Mcl-1(low) profile.
|
21835956 |
2011 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, we provide first time evidence that similar to Fas, TRAIL-induced apoptosis is not blocked by bcl-2 in MM cell lines.
|
10557057 |
1999 |
|
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We studied the cytotoxic effect of TAX and GEM on MM cells expressing varying levels of the antiapoptotic protein bcl-2, which is overexpressed in the majority of myeloma cell from MM patients.
|
9735415 |
1998 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ongoing clinical trials are exploring the role of Bcl-2 downregulation with oblimersen (Bcl-2 antisense) in patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia and multiple myeloma.
|
15784299 |
2005 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As wogonin was effective in vitro in promotion of apoptosis of myeloma cell by Akt-modulated, Bax and Bcl-2 related intrinsic apoptotic pathway, wogonin may be a potential therapeutic agent against multiple myeloma.
|
23142241 |
2013 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We studied eight myeloma cell lines for the presence of Bcl-2, which inhibits apoptosis, of Bax, which counteracts Bcl-2, of Bcl-x(L) and Bcl-x(S), which act in an anti- and pro-apoptotic fashion, respectively, and of Apo-1/Fas, which induces programmed cell death, when activated by the Apo-1/Fas ligand or the relevant monoclonal antibody (mab).
|
9163609 |
1997 |
|
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In contrast, high Bcl-2-expressing myeloma cells were practically resistant to Bcl-2-ASO.
|
12521996 |
2003 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bcl-2 mediated suppression of apoptosis in myeloma NS0 cultures.
|
10812183 |
2000 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Induction of apoptosis and antitumor effects of a small molecule inhibitor of Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro and in vivo.
|
23708869 |
2013 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bcl-2 inhibitors and HDAC inhibitors were proved their anti-MM effect in clinic or under clinical trials, and they were further discovered to have synergistic interactions.
|
30594434 |
2019 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1.
|
11175262 |
2000 |
|
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Multiple myeloma (MM) is a slow-growing malignancy whose plasma cells express the BCL-2 antiapoptosis gene.
|
7743552 |
1995 |
|
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MM.1R and MM.1S cell lines were treated with 15d-PGJ<sub>2</sub> at 1-10μM and evaluated with regard to proliferation, mRNA expression of PRDX1, PRDX4, GRP78, GRP94, CHOP, BCL-2 and BAX.
|
28506771 |
2017 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Myeloid cell leukemia-1 (Mcl-1) protein is an anti-apoptotic Bcl-2 family protein that plays essential roles in multiple myeloma (MM) survival and drug resistance.
|
22128141 |
2012 |
|
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To ascertain if multiple myeloma cells surviving exposure to chemotherapy alter their BCL-2 expression, we treated the myeloma cell lines 8226, IM-9, and U266 as well as a primary myeloma cell culture with various injurious agents.
|
8781438 |
1996 |